Why didn't Wanfu Bio's performance get worse in the third quarter, the fourth quarter and the first quarter of 2022 in 20021year?

The price fluctuation of testing reagent products in COVID-19 affects the decline of gross profit margin and net profit margin.

In 20021year, the company's comprehensive gross profit margin decreased 10.56% to 58.46% year-on-year, among which the gross profit margin of infectious disease detection (including COVID-19 detection) decreased by 2 1.33% to 55.24% year-on-year. We expect that this is mainly due to the decline in the price of detection reagents in COVID-19 in the second half of the year. The sales expense ratio decreased by 3.28pct to 19. 17%, with a year-on-year increase of 2.09%. The management fee increased by 1. 19% to 7.9 1% year-on-year, mainly due to the equity payment fee of 43 19 1600 yuan generated by the company's new employee equity incentive plan, as well as the increase in employee salaries and consulting service fees; The R&D expense ratio increased by 1.70pct to 1 1.64% year-on-year, with an increase of 39.96%, mainly due to the company's increasing talents and R&D investment; The financial expense ratio increased by 0.46pct to 65,438+0.46% year-on-year, mainly for the amortization expense of interest on convertible bonds of RMB24,507,500; Under the comprehensive influence, the overall net interest rate of the company decreased by 3. 12pct to 18.82% year-on-year.